Seroatlas · Human Serome Atlas

MOSMO

Modulator of smoothened protein

Also known as: ATTHOG, BC030336, C16orf52, MOSMO_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8NHV5
Gene: MOSMO
Ensembl: ENSG00000185716
Chromosome: 16
Canonical length: 167 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Predicted to be involved in negative regulation of smoothened signaling pathway; regulation of neuron differentiation; and regulation of protein stability. Predicted to act upstream of or within several processes, including chordate embryonic development; embryonic limb morphogenesis; and smoothened signaling pathway. Predicted to be located in plasma membrane. Predicted to be active in Golgi apparatus and ciliary membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

167 residues, UniProt reviewed canonical sequence.

>Q8NHV5|MOSMO
     1  MDKLTIISGC LFLAADIFAI ASIANPDWIN TGESAGALTV GLVRQCQTIH GRDRTCIPPR
    61  LPPEWVTTLF FIIMGIISLT VTCGLLVASH WRREATKYAR WIAFTGMILF CMAALIFPIG
   121  FYINEVGGQP YKLPNNTVVG SSYVLFVLSI FFTIVGLLFA GKVCLPG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MOSMO can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 4
Mean surface accessibility (rSASA): 0.3
Highest tissue expression: 20 nTPM

Expression across tissuesHPA

Tissue

adrenal gland: 20 nTPM
parathyroid gland: 17 nTPM
cerebral cortex: 14 nTPM
cerebellum: 13 nTPM
liver: 13 nTPM
retina: 12 nTPM

Single-cell type

brain excitatory neurons: 146 nCPM
brain inhibitory neurons: 140 nCPM
other brain neurons: 117 nCPM
choroid plexus epithelial cells: 114 nCPM
oligodendrocyte progenitor cells: 104 nCPM
podocytes: 95 nCPM

Immune cell

naive B-cell: 1 nTPM
T-reg: 0.6 nTPM
eosinophil: 0.4 nTPM
basophil: 0.3 nTPM
gdT-cell: 0.3 nTPM
intermediate monocyte: 0.3 nTPM

Brain region

cerebral cortex: 38 nTPM
cerebellum: 34 nTPM
white matter: 30 nTPM
basal ganglia: 25 nTPM
hippocampal formation: 24 nTPM
thalamus: 24 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.82
gnomAD pLI: 0.26
DepMap mean gene effect: 0.06
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

Modulator of smoothened protein
Attenuator of Hedgehog

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MOSMO as an antibody target. Whether an autoantibody or antibody against MOSMO could matter depends on whether native MOSMO is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MOSMO is annotated at the cell surface, where native MOSMO is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label MOSMO as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...